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Summary
Background: COVID-19 is an ongoing threat to society. Patients who develop the most severe forms of the disease have high
mortality. The interleukin-6 inhibitor tocilizumab has the potential to improve outcomes in these patients by preventing
the development of cytokine release storm.
Aims: To evaluate the outcomes of patients with severe COVID-19 disease treated with the interleukin-6 inhibitor
tocilizumab.
Methods: We conducted a retrospective, case–control, single-center study in patients with severe to critical COVID-19 disease treated with tocilizumab. Disease severity was defined based on the amount of oxygen supplementation required. The
primary endpoint was the overall mortality. Secondary endpoints were mortality in non-intubated patients and mortality
in intubated patients.
Results: A total of 193 patients were included in the study. Ninety-six patients received tocilizumab, while 97 served as the control group. The mean age was 60 years. Patients over 65 years represented 43% of the population. More patients in the tocilizumab group reported fever, cough and shortness of breath (83%, 80% and 96% vs. 73%, 69% and 71%, respectively). There was a
non-statistically significant lower mortality in the treatment group (52% vs. 62.1%, P ¼ 0.09). When excluding intubated patients,
there was statistically significant lower mortality in patients treated with tocilizumab (6% vs. 27%, P ¼ 0.024). Bacteremia was
more common in the control group (24% vs. 13%, P ¼ 0.43), while fungemia was similar for both (3% vs. 4%, P ¼ 0.72).
Conclusion: Our study showed a non-statistically significant lower mortality in patients with severe to critical COVID-19 disease
who received tocilizumab. When intubated patients were excluded, the use of tocilizumab was associated with lower mortality.
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Introduction
The global pandemic caused by the novel coronavirus SARSCoV-2 (COVID-19) has spread to over 185 countries, with more
than 7.5 million infections and over 420 000 deaths globally. In
the USA alone, over 113 000 people have died from this disease.1
The majority of infected patients have only mild or no symptoms at all. Approximately 19% of patients develop severe or
critical disease.2 Higher risk of mortality has been reported
among patients with advanced age, male gender and those with
underlying comorbidities, such as hypertension, coronary artery
disease, heart failure, diabetes mellitus and chronic lung
disease.3,4
The case fatality rate (CFR) for COVID-19 has been reported
to be around 2.3%. This number increases to 6–10% in the presence of chronic cardiovascular and pulmonary conditions.2 In
patients admitted to the intensive care unit (ICU) who require
intubation, the CFR can range from 26% to 88%.2,5–7
One of the most accepted explanations for the development
of severe COVID-19 disease is an overproduction of proinflammatory cytokines. Autopsy studies in patients who died of
Severe Acute Respiratory Syndrome (SARS) and Middle Eastern
Respiratory Syndrome (MERS) have suggested that aberrant
host immune response results in an inflammatory cytokine
storm and lethal disease.8 Several studies in patients with
severe COVID-19 disease have shown an increased plasma
concentration of inflammatory cytokines, including interleukin
(IL)-6, IL-2, IL-10, interferon gamma and tumor necrosis factor
alpha.9,10
Studies have reported that patients with severe COVID-19
disease have experienced rapid resolution of fever and improvement in oxygenation after treatment with tocilizumab.7,11 This
is a recombinant humanized anti-human IL-6 receptor monoclonal antibody that binds to the IL-6 receptor with high affinity.
Tocilizumab is currently FDA-approved in the USA for the management of rheumatoid arthritis and chimeric antigen receptor
T-cell-induced cytokine release syndrome. No clinical study has
reported the use of tocilizumab among hospitalized patients
with severe COVID-19 infection in the USA.
We retrospectively analyzed the outcomes of severe COVID19 disease among patients who received tocilizumab under
compassionate use.
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nasal cannula up to 5 l/min to maintain an oxygen saturation of
at least 95%. Severe disease was defined as requiring oxygen
supplementation via face mask up to 10 l/min to maintain an
oxygen saturation of 95% or higher. Very severe disease was
defined by requiring a non-rebreather mask or high-flow nasal
cannula to maintain an oxygen saturation of 95% or higher.
Critical disease was defined by the need for intubation and
mechanical ventilation. All interventions were done as part of
regular patient care.
A control group of 97 patients with PCR-confirmed COVID-19
disease who had not received tocilizumab was included.
Patients in the control group were required to be on supplemental oxygen that matched the treatment group. Individuals who
died within 24 h of admission and those included in clinical trials with other biologic agents or convalescent plasma were
excluded from the analysis.
Data were collected from the hospital’s electronic medical
record (Sunrise Clinical Manager). To ensure quality control, we
performed manual data entry. The information collected
included patients’ demographics, presenting symptoms, comorbidities, home medications, initial vital signs, laboratory tests,
treatment for COVID-19, and outcomes, including length of hospital stay, complications and mortality.

Endpoints
The primary endpoint was the overall mortality rate. Secondary
endpoints were mortality in non-intubated patients only and
mortality in intubated patients.

Statistical analysis
Statistical analyses were performed using Statistical Package for
the Social Sciences (SPSS), version 26.0 (SPSS Inc., Chicago, IL,
USA). Descriptive statistics were provided for all variables and
presented as mean 6 standard deviation for continuous variables and as number and percentage for categorical variables.
Statistical tests of significance (Student’s t-test for continuous
variables and the v2 test or Fischer’s exact test for categorical
variables) were conducted to assess differences between the
cohorts (treatment vs. control groups). A two-tailed P values
0.05 was regarded as statistically significant.

Methods

Results

Study site

Demographic and clinical characteristics

The study was conducted at Maimonides Medical Center, a 711bed tertiary care teaching hospital in Brooklyn, NY, USA. The
Maimonides Medical Center institutional review board
approved the study. The need for informed consent was waived
based on the study’s retrospective nature and designation as
minimal-risk research.

The demographic and clinical characteristics are shown in
Table 1. A total of 193 patients were included in the study; 96
patients received the IL-6 inhibitor tocilizumab, while 97
patients served as the control group. The mean age was
60 years. Patients over 65 years of age represented 43% of the
study population (37% in the treatment group vs. 49% in the
control). Hypertension was present in 54%. Other comorbidities
included diabetes (35%), atrial fibrillation (6%), heart failure
(12%) and COPD (6%).
At presentation, more patients in the treatment group
reported fever, cough and shortness of breath (83%, 80% and
96% vs. 73%, 69% and 71%, respectively). The average pulse oximetry oxygen saturation on admission was 84 6 11 in the treatment group versus 88 6 12 in the control group. The level of
blood urea nitrogen was higher in the control group (25.9 6 18.8
vs. 19.1 6 10.7, P ¼ 0.002). The initial CRP level was higher in the
treatment group, but this was not statistically significant
(17.1 6 8.9 vs. 14.6 6 9.6, P ¼ 0.074). The admission values for

Patient selection and data collection
We analyzed the information of adult patients hospitalized
with severe to critical SARS-CoV-2 infection (COVID-19) who
received tocilizumab between 8 March and 25 April 2020. The
accepted method for diagnosis of COVID-19 was polymerase
chain reaction (PCR) testing of a nasopharyngeal sample.
Disease severity was defined based on the amount of oxygen
supplementation required. Mild disease was defined as having
an oxygen saturation above 95% on room air. Moderate disease
referred to patients who required oxygen supplementation via
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Table 1. Baseline and clinical characteristics
Total
(N ¼ 193)
Characteristic or condition
Age (years)
Age >65 years, n (%)
Male gender, n (%)
Race or ethnic group, n (%)
White
Black
Hispanic
Asian
Coexisting conditions, n (%)
Hypertension
Diabetes
Stroke
Atrial fibrillation
Heart failure
Asthma
COPD
Active smoker
Active medications
ACEi/ARB
Anticoagulation
Betablockers
Presenting symptoms
Fever
Cough
Shortness of breath
Myalgia
Vital signs
Oxygen saturation (%)
Respiratory rate (breaths/min)
Disease severity—oxygen requirement, n (%)
Mild disease—no oxygen required
Moderate disease—nasal cannula
Severe disease—face mask up to 10 l/min
Very severe disease—non-rebreather/high flow nasal cannula
Critical disease—intubated patients
Laboratory values
White blood cell count (K/ml)
Lymphocyte count (%)
C-reactive protein (mg/dl)
Ferritin (Ng/ml)
D-dimer (Ng/ml)
Troponin I (Ng/ml)
Procalcitonin (Ng/ml)

Tocilizumab group
(N ¼ 96)

Control group
(N ¼ 97)

P-value

60.4 6 13.8
82 (42.5)
137 (71)

58.8 6 13.6
35 (36.5)
74 (77.1)

62.0 6 14
47 (48.5)
63 (64.9)

0.11
0.09
0.06

106 (54.9)
17 (8.8)
34 (17.6)
19 (9.8)

49 (51.0)
7 (7.3)
16 (16.7)
10 (10.4)

57 (58.8)
10 (10.3)
18 (18.6)
9 (9.3)

104 (53.9)
67 (34.7)
7 (3.6)
11 (5.7)
18 (9.3)
13 (6.7)
11 (5.7)
2 (1.0)

53 (55.2)
29 (30.2)
4 (4.2)
4 (4.2)
7 (7.3)
4 (4.2)
8 (8.3)
2 (2.1)

51 (52.6)
38 (39.2)
3 (3.1)
7 (7.2)
11 (11.3)
9 (9.3)
3 (3.1)
0

0.71
0.19
0.72
0.36
0.33
0.15
0.11
0.24

64 (33.2)
18 (9.3)
60 (31.1)

36 (37.5)
9 (9.4)
32 (33.3)

28 (28.9)
9 (9.3)
28 (28.9)

0.2
0.98
0.5

151 (78.2)
144 (74.6)
161 (83.4)
37 (19.2)

80 (83.3)
77 (80.2)
92 (95.8)
24 (25)

71 (73.2)
67 (69.1)
69 (71.1)
13 (13.4)

0.08
0.07
<0.001
0.04

86 6 12
28 6 8

84 6 11
30 6 8

88 6 12
26 6 8

0.01
0.003

1 (0.5)
11 (5.7)
6 (3.1)
59 (30.6)
121 (62.7)

0
6 (6.3)
0
29 (30.2)
61 (63.5)

1 (1)
5 (5.2)
6 (6.2)
30 (30.9)
60 (61.9)

0.31
0.74
0.02
0.91
0.8

8.7 6 4.4
12.5 6 9.1
15.9 6 9.3
1014 6 1072
1839 6 1951
0.19 6 1.16
1.54 6 5.01

8.9 6 4.4
12.4 6 9.6
17.1 6 8.9
1023 6 934
1672 6 2137
0.10 6 0.41
1.09 6 1.93

8.5 6 4.5
12.6 6 8.7
14.6 6 9.6
1004 6 1204
2228 6 1392
0.28 6 1.59
2.02 6 6.90

0.5
0.89
0.07
0.9
0.19
0.29
0.23

0.42

ACEi, angiotensin–converting–enzyme inhibitors; ARB, angiotensin receptor blockers.

white blood cell count, lymphocyte count, ferritin level, D-dimer
and troponin I were similar in both groups.

Management for COVID-19
Management of COVID-19 is detailed in Table 2. Most patients
in both groups received hydroxychloroquine and azithromycin
(92% and 92% for the treatment group and 97% and 94% for the
control group). Corticosteroids were given to 43% of patients in
the treatment group versus 33% in the control group (P ¼ 0.16).
Full-dose anticoagulation was used in 59% and 48% in the treatment and control groups, respectively (P ¼ 0.2). Remdesivir was
used in 13% of patients in the treatment group versus 9% in the
control group. Antibiotics for suspected bacterial infections

were used in 94% in the treatment group and 89% in the control
group. Vasopressors were used in 60% of patients in the treatment group versus 47% in the control group. Twenty-two percent of patients in the treatment group developed acute renal
failure that required renal replacement therapy (RRT); this
occurred in 13% of patients in the control group.

Outcomes
There was a non-statistically significant reduced mortality in
the treatment group (52% vs. 62%, P ¼ 0.09) (Table 3). When
excluding intubated patients, those in the treatment group had
a lower mortality (6% vs. 27%, P ¼ 0.024). The length of hospital
stay, excluding patients who remained hospitalized at the time
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Table 2. Treatment for COVID-19
Medication, n (%)
Hydroxychloroquine
Azithromycin
Corticosteroids
Full-dose anticoagulation
Remdesivir
Vitamin C
Zinc
Both
Antibiotics for suspected bacterial infection

Total (N ¼ 193)

Tocilizumab group (N ¼ 96)

Control group (N ¼ 97)

P-value

183 (94.8)
180 (93.3)
73 (37.8)
104 (53.8)
21 (10.9)
28 (14.5)
30 (15.5)
84 (43.5)
176 (91.2)

89 (92.7)
89 (92.7)
41 (42.7)
57 (59.4)
12 (12.5)
18 (18.8)
9 (9.4)
50 (52.1)
90 (93.8)

94 (96.6)
91 (93.8)
32 (33)
47 (48.5)
9 (9.3)
10 (10.3)
21 (21.6)
34 (35.1)
86 (88.7)

0.21
0.09
0.164
0.2
0.47
0.004
0.21

Table 3. Outcomes
Outcomes, N (%)

Total
(N ¼ 193)

Tocilizumab group
(N ¼ 96)

Control group
(N ¼ 97)

Overall mortality
Mortality in non-intubated patients (excluding patients still hospitalized)
Mortality in intubated patients (excluding patients still hospitalized)
Length of stay, excluding patients still hospitalized (days 6 SD)
Bacteremia
Fungemia
Renal replacement therapy (RRT)
Need for ECMO
Need for vasopressors

98 (50.8)
11 (16.4)
86 (71)
15.3 6 9.9
35 (18.1)
7 (3.6)
35 (18.1)
1 (0.5)
113 (58.5)

43 (44.8)
2 (6.1)
41 (67.2)
14.5 6 8.8
12 (12.5)
4 (4.2)
22 (22.9)
1 (1)
59 (61.5)

55 (56.7)
9 (26.5)
45 (75)
16.5 6 10.8
23 (23.7)
3 (3.1)
13 (13.4)
0
54 (55.7)

of submission, was lower in the treatment group; however, this
finding was not statistically significant (15 vs. 17 days, P ¼ 0.32).
Bacteremia was more commonly found in the control group
(23.7% vs. 12.5%, P ¼ 0.04), whereas fungemia was similar in
both groups (4% vs. 3% P ¼ 0.7). More patients in the treatment
group required RRT; however, this was not statistically significant (23% vs. 13%, P ¼ 0.08). There was no difference in the use
of vasopressors (62% vs. 56%, P ¼ 0.41).

Discussion
We analyzed the clinical characteristics and outcomes of 96
patients with severe to critical COVID-19 disease who received a
single dose of the IL-6 inhibitor tocilizumab as part of their
treatment. A group of 97 consecutive patients with confirmed
severe to critical COVID-19 disease served as the control group.
Our study shows an overall mortality rate of 51%. This
ranged from 16% in non-intubated patients to 71% in those who
required intubation and mechanical ventilation. Patients in the
treatment group had lower mortality than those in the control
group; however, this was not statistically significant. When
intubated patients were excluded, mortality was significantly
lower in the treatment group.
Several authors have reported the potential benefits of tocilizumab in patients with COVID-19 disease.7,11,12 Xu et al.7
described their experience with this agent in 21 patients considered to have severe to critical COVID-19 disease. Their sample
included two patients (10%) on mechanical ventilation and
seven (35%) on oxygen supplementation via nasal cannula.
Oxygen supplementation was de-escalated within 5 days from
drug administration in 15 out of 20 patients (75%). All patients
were discharged alive, and no significant adverse effects from
the medication were reported. In another case series with 15
patients, three out of seven subjects (42%) classified as having

P-value

0.09
0.024
0.34
0.329
0.04
0.72
0.08
0.49
0.41

critical COVID-19 disease died despite receiving tocilizumab.
The rest of the patients were reported to have a fast recovery.
One-third of the patients received more than one dose of the
medication.11 These authors highlight the potential benefit of
tocilizumab when its use is implemented before the disease is
too advanced. This is further underscored by the results
reported by Capra et al.13 In a cohort of non-intubated patients
with COVID-19 disease, they found a lower mortality rate (8%
vs. 57.9%) in those treated with tocilizumab.
Our findings correlate with these other reports. The use of
tocilizumab did not affect the mortality rate in patients who
were intubated. However, in the non-intubated population, the
use of tocilizumab was associated with a lower mortality. None
of the patients in our study received more than one dose of tocilizumab. Some authors propose using more than one dose of
the medication in patients with persistently elevated inflammatory markers.7,11
In a case–control study with 20 patients treated with tocilizumab, Klopfenstein et al.14 described a lower composite endpoint of mortality and ICU admission in the tocilizumab group.
This difference was driven by a higher percentage of ICU admissions in the standard therapy group (44% vs. 0%, P  0.001).
When analyzed separately, the difference in mortality was not
statistically significant.
In another study, Toniati et al.15 reported their results on 100
consecutive patients treated with multiple doses of tocilizumab
for severe to critical COVID-19 disease. They found a mortality
of 18% in patients receiving non-invasive ventilation (severe
and very severe disease). This is higher than the 6% found in
our study. In those who were intubated, they reported a mortality of 24%. Only 15 patients were reported as being discharged
(15%), suggesting that a significant number of patients might
not have had a definitive outcome at the time of the analysis. In
contrast to these findings, Colaneri et al.16 found no difference
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in ICU admission or mortality in patients with severe COVID-19
disease treated with tocilizumab. They conducted a case–control study with 21 patients treated with the drug and 21 propensity score-matched controls.
Some pitfalls of most of the previously reported studies are
either a small sample size, lack of a control group or both. Our
study represents the largest case–control study of patients with
severe COVID-19 disease treated with tocilizumab in the USA.
A valid concern regarding the use of tocilizumab, and other
biologic agents, is the risk of infections. Studies done in patients
with rheumatologic disorders have reported a potential risk for
developing serious infections with the use of tocilizumab.17,18
Our study showed a lower rate of bacteremia in the treatment
group and a similar rate of fungemia in both groups.

Limitations
Our study has several limitations that are inherent to its retrospective nature. First, the control and treatment groups were
not matched. This could potentially explain the lack of benefit
in intubated subjects. More patients in the treatment group
were of male sex, reported more fever, cough and shortness of
breath and presented with lower oxygen saturation. Despite
these differences, patients with lower disease severity (nonintubated) did show better outcomes. Second, we excluded
patients who received other biologic agents and convalescent
plasma. This could represent a selection bias. However, our intention was to assess the outcomes with tocilizumab alone.
Third, our treatment group received only one dose of tocilizumab, while other studies have reported the use of multiple
doses. Currently, there is no consensus on the correct dose or
timing of administration for tocilizumab.

Conclusions
Our study showed a non-significant trend toward lower mortality in patients with severe to critical COVID-19 disease treated
with tocilizumab. When intubated patients were excluded,
those who received tocilizumab had a lower mortality.
Randomized clinical trials are needed to confirm these and
other findings and provide more information regarding dosing,
short- and long-term adverse effects, and proper timing of
administration.
Conflict of interest: The authors declare that there is no conflict of
interest regarding the publication of this article. .
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